piracetam has been researched along with Adenocarcinoma in 1 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 7.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 3.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taberner Bonastre, MT | 1 |
| Peralta Muñoz, S | 1 |
| Boza, FM | 1 |
| Gumà I Padró, J | 1 |
1 other study available for piracetam and Adenocarcinoma
| Article | Year |
|---|---|
Neutropenia secondary to exposure to levetiracetam.
Topics: Adenocarcinoma; Anticonvulsants; Brain Neoplasms; Craniotomy; Drug Administration Schedule; Humans; | 2015 |